share_log

HC Wainwright & Co. Initiates Coverage On TransCode Therapeutics with Buy Rating, Announces Price Target of $10

HC Wainwright & Co. Initiates Coverage On TransCode Therapeutics with Buy Rating, Announces Price Target of $10

HC Wainwright & Co.以买入评级启动对TransCode Therapeutics的报道,宣布目标股价为10美元
Benzinga Real-time News ·  2022/06/07 06:24

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on TransCode Therapeutics (NASDAQ:RNAZ) with a Buy rating and announces Price Target of $10.

HC Wainwright & Co. 分析师艾米丽·博德纳尔以买入评级开始对TransCode Therapeutics(纳斯达克股票代码:RNAZ)进行报道,并宣布目标股价为10美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发